PLGA Based Drug Carrier and Pharmaceutical Applications

Poly(lactic-co-glycolic acid) (PLGA) is one of the most successful polymers used for producing therapeutic devices, such as drug carriers (DC). PLGA is one of the few polymers that the Food and Drug Administration (FDA) has approved for human administration due to its biocompatibility and biodegrada...

Full description

Saved in:
Bibliographic Details
HerausgeberIn:
Sonstige:
Year of Publication:2021
Language:English
Physical Description:1 electronic resource (328 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 05509nam-a2201525z--4500
001 993545575204498
005 20231214133254.0
006 m o d
007 cr|mn|---annan
008 202105s2021 xx |||||o ||| 0|eng d
035 |a (CKB)5400000000040814 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/68416 
035 |a (EXLCZ)995400000000040814 
041 0 |a eng 
100 1 |a Pereira, Maria Carmo  |4 edt 
245 1 0 |a PLGA Based Drug Carrier and Pharmaceutical Applications 
260 |a Basel, Switzerland  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2021 
300 |a 1 electronic resource (328 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
520 |a Poly(lactic-co-glycolic acid) (PLGA) is one of the most successful polymers used for producing therapeutic devices, such as drug carriers (DC). PLGA is one of the few polymers that the Food and Drug Administration (FDA) has approved for human administration due to its biocompatibility and biodegradability. In recent years, DC produced with PLGA has gained enormous attention for its versatility in transporting different type of drugs, e.g., hydrophilic or hydrophobic small molecules, or macromolecules with a controlled drug release without modifying the physiochemical properties of the drugs. These drug delivery systems have the possibility/potential to modify their surface properties with functional groups, peptides, or other coatings to improve the interactions with biological materials. Furthermore, they present the possibility to be conjugated with specific target molecules to reach specific tissues or cells. They are also used for different therapeutic applications, such as in vaccinations, cancer treatment, neurological disorder treatment, and as anti-inflammatory agents. This book aims to focus on the recent progress of PLGA as a drug carrier and their new pharmaceutical applications. 
546 |a English 
650 7 |a Medicine  |2 bicssc 
653 |a PLGA 
653 |a nanoscaled drug delivery 
653 |a LED 
653 |a cancer 
653 |a serum stability 
653 |a reactive oxygen species 
653 |a cellular uptake 
653 |a terahertz spectroscopy 
653 |a microspheres 
653 |a drug delivery 
653 |a formulation development 
653 |a molecular mobility 
653 |a vitamin E 
653 |a tocopherol 
653 |a PLA 
653 |a core-shell nanoparticles 
653 |a controlled drug release 
653 |a BMP-2 
653 |a PLGA nanoparticles 
653 |a Pluronic F68 
653 |a oxaliplatin 
653 |a hydrogel 
653 |a intra-abdominal anti-adhesion barrier 
653 |a colorectal cancer 
653 |a experimental design 
653 |a fractional factorial design 
653 |a O6-methylguanine DNA methyltransferase (MGMT) protein 
653 |a glioblastoma multiforme 
653 |a smart nanocarriers 
653 |a folic acid 
653 |a verteporfin 
653 |a cisplatin 
653 |a SKOV-3 cells 
653 |a CHO-K1 cells 
653 |a electroporation 
653 |a theranostic cargo 
653 |a double emulsion approach 
653 |a NSAIDs 
653 |a polymeric film 
653 |a topical drug delivery 
653 |a trolamine salicylate 
653 |a triamcinolone acetonide 
653 |a microcrystal 
653 |a PLGA microsphere 
653 |a local delivery 
653 |a spray-drying technique 
653 |a intra-articular injection 
653 |a joint retention 
653 |a systemic exposure 
653 |a gadolinium 
653 |a drug release 
653 |a polymeric nanocarrier 
653 |a sorafenib 
653 |a theranostic nanoparticles 
653 |a PLGA-PEG 
653 |a nanoparticles 
653 |a platelet 
653 |a activation 
653 |a aggregation 
653 |a binding 
653 |a uptake 
653 |a tissue engineering 
653 |a Huntington's disease 
653 |a siRNA 
653 |a microcarriers 
653 |a mesenchymal stromal cells 
653 |a drug delivery systems 
653 |a microfluidics 
653 |a microparticles 
653 |a BMP-2-microspheres 
653 |a hydrogel system 
653 |a 17-βestradiol release 
653 |a bone regeneration 
653 |a osteoporosis 
653 |a poly-lactide-co-glycolide 
653 |a polylactic acid 
653 |a alginate 
653 |a ophthalmic drug delivery 
653 |a dexamethasone 
653 |a PLGA-NPs 
653 |a nanomedicine 
653 |a gastrointestinal tract 
653 |a paclitaxel 
653 |a in vivo imaging 
653 |a controlled release 
653 |a risperidone 
653 |a microcapsules 
653 |a oleogels 
653 |a electron microscopy 
653 |a three-dimensional X-ray imaging 
653 |a nano-CT 
653 |a biodegradable polymers 
653 |a hydroxy-stearic acid 
653 |a PLGA nanocapsules 
653 |a magnetic resonance imaging 
653 |a photoluminescence 
653 |a magnetic targeting 
653 |a multimodal imaging 
653 |a theranostics 
653 |a silicon 
653 |a microsphere 
776 |z 3-0365-0220-3 
776 |z 3-0365-0221-1 
700 1 |a Loureiro, Joana  |4 edt 
700 1 |a Pereira, Maria Carmo  |4 oth 
700 1 |a Loureiro, Joana  |4 oth 
906 |a BOOK 
ADM |b 2023-12-15 05:48:47 Europe/Vienna  |f system  |c marc21  |a 2022-04-04 09:22:53 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337985080004498&Force_direct=true  |Z 5337985080004498  |b Available  |8 5337985080004498